GPR119

Glucose-dependent insulinotropic receptor · Q8TDV5 · GPR119 on Sugi Atlas →

259,384 patent compounds predicted against GPR119, 84,002 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL114213 SCHEMBL114213 1.00 20/20
SCHEMBL288614 SCHEMBL288614 1.00 20/20
SCHEMBL288892 SCHEMBL288892 1.00 20/20
SCHEMBL287689 SCHEMBL287689 0.81 20/20
SCHEMBL288589 SCHEMBL288589 0.80 20/20
SCHEMBL289195 SCHEMBL289195 0.76 20/20
SCHEMBL288618 SCHEMBL288618 0.75 20/20
SCHEMBL288058 SCHEMBL288058 0.73 20/20
SCHEMBL288167 SCHEMBL288167 0.70 20/20
SCHEMBL288948 SCHEMBL288948 0.65 20/20
SCHEMBL288318 SCHEMBL288318 0.61 20/20
SCHEMBL288366 SCHEMBL288366 0.60 20/20
SCHEMBL288373 SCHEMBL288373 0.58 20/20
SCHEMBL288503 SCHEMBL288503 0.57 20/20
SCHEMBL288936 SCHEMBL288936 0.57 20/20
SCHEMBL288249 SCHEMBL288249 0.57 20/20
SCHEMBL288620 SCHEMBL288620 0.56 20/20
SCHEMBL148647 SCHEMBL148647 0.55 20/20
SCHEMBL121348 SCHEMBL121348 0.52 20/20
SCHEMBL174827 SCHEMBL174827 0.51 20/20

Clinical trials — most relevant to GPR119 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) PHASE4NOT_YET_RECRUITING
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA) PHASE3COMPLETED
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion PHASE3COMPLETED
GPR119 Agonist for Hypoglycemia in Type 1 Diabetes PHASE2COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment PHASE1/PHASE2RECRUITING
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes PHASE2RECRUITING
The Role of Endocannabinoids in Insulin Production and Action PHASE1COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Satiation Peptides PHASE1COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY PHASE1COMPLETED
Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans PHASE1COMPLETED
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY PHASE1COMPLETED
Diet Oil Induced Stimulation of GLP-1 EARLY_PHASE1COMPLETED
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans. nanCOMPLETED
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation nanCOMPLETED
-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans. nanCOMPLETED
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance nanUNKNOWN
Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients nanENROLLING_BY_INVITATION
Growth Hormone Signaling in Vivo in Humans nanCOMPLETED
Hepatic Metabolic Changes in Response to Glucagon Infusion nanCOMPLETED
Investigating Glucose Metabolism of LEAP2 With Total-body PET/CT nanACTIVE_NOT_RECRUITING
The Importance of Ghrelin for Glucose Metabolism After Sleeve Gastrectomy nanCOMPLETED
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD nanRECRUITING
Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs nanACTIVE_NOT_RECRUITING
Effects of Obesity and Intensity of Exercise on Ghrelin Levels nanCOMPLETED
Glucose Response, Excursions And Treatment (GREAT) Study nanCOMPLETED
Separate and Combined Extrapancreatic Effects of the Incretin Hormones nanCOMPLETED
Effects of Polyphenols Found in Pomegranate and Olives Food Supplements on Postprandial Blood Glucose in Vivo. nanCOMPLETED
Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a GPR119 binder may also engage these)

ProteinNameSimilarity
Q7TQP3 1.000 Q7TQP3 →
CNR2 Cannabinoid receptor 2 0.985 landscape →
Q9QZN9 0.983 Q9QZN9 →
P56448 0.981 P56448 →
P47936 0.980 P47936 →
P55167 0.979 P55167 →
Q864K5 0.979 Q864K5 →
Q0Q460 0.979 Q0Q460 →
Q6A155 0.979 Q6A155 →
P56447 0.978 P56447 →
Q864K7 0.978 Q864K7 →
O19037 0.977 O19037 →
Q864G2 0.977 Q864G2 →
Q864L0 0.977 Q864L0 →
Q91178 0.977 Q91178 →
Q864K2 0.976 Q864K2 →
O77616 0.976 O77616 →
Q864K3 0.976 Q864K3 →
Q9TUK4 0.976 Q9TUK4 →
Q864J0 0.976 Q864J0 →
Q01727 0.975 Q01727 →
Q864J7 0.975 Q864J7 →
Q864G6 0.975 Q864G6 →
Q864F9 0.975 Q864F9 →
Q864K6 0.975 Q864K6 →
P56445 0.975 P56445 →
P56442 0.974 P56442 →
Q864K8 0.974 Q864K8 →
Q864K4 0.974 Q864K4 →
Q80SS9 0.974 Q80SS9 →